Open-Label Extension Protocol to SNK01-AD01 Study

Part of paid clinical trials in Glendale, California.

Sponsor
NKGen Biotech, Inc.
Study ID
NCT07228078
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
40 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • SNK01 — BIOLOGICAL
    SNK01 is a novel cell-based, patient specific ex vivo expanded autologous natural killer (NK) cell, immunotherapeutic drug

Study Details

Open-Label Extension Protocol to SNK01-AD01 Study

Key Dates

Start date
Jun 30, 2025
Status verified
Nov 2025
Primary completion
Apr 30, 2028
Completion
Apr 30, 2028

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Open-Label
    SNK01

Primary Outcome Measure

Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 [ Time Frame: 1 Year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Behavioral Research Specialists, LLCGlendaleCalifornia91206
Harry Chung
[email protected]
(888) 255-5798

Find similar trials in Glendale, CA

By condition
Alzheimer's disease
By specialty
NeurologyDementia careBrain disordersGeriatrics
By research site
Behavioral Research Specialists, LLC· Glendale, CA

Related Studies